Fiera Capital (Canada)
XENE icon

Fiera Capital (Canada)’s Xenon Pharmaceuticals XENE Stock Holding History

Fiera Capital (Canada)’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5M Sell
405,638
-303,891
-43% -$16.9M 0.09% 156
2026
Q1 		$41.3M Buy
709,529
+23,473
+3% +$1.08M 0.14% 129
2025
Q4 		$30.7M Buy
686,056
+166,057
+32% +$6.97M 0.1% 156
2025
Q3 		$20.9M Sell
519,999
-10,684
-2% -$376K 0.07% 162
2025
Q2 		$16.6M Buy
530,683
+1,241
+0.2% +$40.5K 0.06% 164
2025
Q1 		$17.8M Sell
529,442
-6,445
-1% -$245K 0.06% 162
2024
Q4 		$21M Sell
535,887
-18,313
-3% -$757K 0.07% 147
2024
Q3 		$21.8M Sell
554,200
-28,679
-5% -$1.16M 0.07% 150
2024
Q2 		$22.7M Buy
582,879
+6,337
+1% +$253K 0.07% 141
2024
Q1 		$24.8M Buy
576,542
+23,512
+4% +$1.08M 0.07% 140
2023
Q4 		$25.5M Sell
553,030
-7,516
-1% -$266K 0.08% 137
2023
Q3 		$19.1M Buy
560,546
+11,205
+2% +$419K 0.06% 151
2023
Q2 		$21.1M Buy
+549,341
New +$21.8M 0.06% 144

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fiera Capital (Canada)'s XENE Position: Q2 2026 in Review

Fiera Capital (Canada) reduced its Xenon Pharmaceuticals (XENE) stake by 43% in Q2 2026, selling an estimated $16.9M and leaving 405,638 shares worth $24.5M. The position accounts for 0.09% of the portfolio, ranked #156.

Fiera Capital (Canada) first reported a position in XENE in Q2 2023 and has held it in 13 quarters since. The position peaked at $41.3M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Fiera Capital (Canada) held 405,638 shares of Xenon Pharmaceuticals worth $24.5M as of Q2 2026.
  • Fiera Capital (Canada) sold 303,891 Xenon Pharmaceuticals shares in Q2 2026, an estimated $16.9M.
  • Xenon Pharmaceuticals made up 0.09% of Fiera Capital (Canada)'s portfolio in Q2 2026, its #156 holding.
  • Fiera Capital (Canada) first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Fiera Capital (Canada)'s Xenon Pharmaceuticals position peaked at $41.3M in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Fiera Capital (Canada)'s 13F filing for Q2 2026, filed 7 Aug 2026.